Insight

KPMG Life Sciences

Experience in cell & gene therapies.

Kristin C. Pothier

Kristin C. Pothier

Global and National Leader, HCLS Strategy, KPMG LLP

+1 617 549 2779

Jeff Stoll, PhD

Jeff Stoll, PhD

Principal, National Strategy Life Sciences Leader, KPMG US

+1 617-988-1000

Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419

At KPMG, we are assisting clients working at the forefront of the next generation of therapies - cell and gene technologies. While these technologies are transforming patient care for certain diseases, they also bring their own unique complexities. KPMG brings a holistic view to the challenges and opportunities associated with the development, manufacturing, supply, pricing, and commercialization of these therapies. We continue to support clients, from small biotechs to large biopharma, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and also private investors, to help them successfully negotiate these challenges and seize the opportunities that cell and gene therapies present.